HU/SCID MOUSE MODEL: PREDICTING IMMUNOTHERAPY RESPONSES

HU/SCID 小鼠模型：预测免疫治疗反应

• 批准号: 3489191
• 负责人: HEINZ KOHLER
• 金额: $ 5万
• 依托单位: IDEC PHARMACEUTICALS CORPORATION
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-08-01 至 1991-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489191
• 关键词: B lymphocyte; T lymphocyte; active immunization; antiidiotype antibody; human subject; laboratory mouse; melanoma; model design /development; monoclonal antibody; neoplasm /cancer immunotherapy; nonhuman therapy evaluation

Active immunotherapy using anti-idiotypic antibodies which mimic tumor- associated antigens has been shown to be effective in animals and patients. Our proposed research is aimed at optimizing the clinical response of malignant melanoma patients to anti-idiotypic immunotherapy currently under development at IDEC. This will be achieved by "idiotype matching" a therapeutic antibody from a panel of anti-idiotypic antibodies with the individual idiotypic repertoire of the patient. We propose to develop an assay quantitatively determines the frequency of idiotype- responsive B and T cells in prospective idiotype therapy patients. SCID mice will be reconstituted with the peripheral blood lymphocytes from melanoma patients. We will then use the splenic focus assay to determine the frequency of lymphocytes responsive to anti-idiotypic monoclonal antibodies. Furthermore, this SCID splenic focus assay will allow us to analyze the patient's T cell repertoire with respect to T helper cell responses. These "idiotype matching" assays will allow the oncologist to make a rational choice of anti-idiotypic antibodies for immunotherapy of malignant melanoma.

使用模拟肿瘤的抗独特型抗体的主动免疫疗法- 相关抗原已被证明在动物中有效， 患者 我们提出的研究旨在优化临床 恶性黑色素瘤患者对抗独特型免疫治疗的反应 目前正在IDEC开发。 这将通过"独特型"来实现 从一组抗独特型抗体中匹配"治疗性抗体 与患者的个体特征库相匹配。 我们建议 开发一种定量测定独特型频率的方法- 前瞻性独特型治疗患者中的应答性B和T细胞。 SCID 小鼠将用来自以下的外周血淋巴细胞重建： 黑色素瘤患者。 然后我们将使用脾病灶测定来确定 对抗独特型单克隆抗体应答的淋巴细胞频率 抗体的 此外，这种SCID脾病灶测定将使我们能够 分析患者的T细胞库， 应答 这些"独特型匹配"测定将允许肿瘤学家 合理选择抗独特型抗体用于免疫治疗 恶性黑素瘤

项目成果

Response of huSCID mice reconstituted with lymphocytes from anti-idiotype-treated melanoma patients.

用来自抗独特型治疗的黑色素瘤患者的淋巴细胞重建的 huSCID 小鼠的反应。

• DOI: 10.1016/s0090-1229(05)80005-4
• 发表时间: 1991
• 期刊: Clinical immunology and immunopathology
• 作者: Norton,FL;Shuey,SR;Köhler,H
• 通讯作者: Köhler,H